Short Interest in DexCom, Inc. (NASDAQ:DXCM) Declines By 5.7%

DexCom, Inc. (NASDAQ:DXCM) was the target of a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 8,800,000 shares, a decrease of 5.7% from the December 15th total of 9,330,000 shares. Based on an average daily volume of 3,910,000 shares, the short-interest ratio is currently 2.3 days.

Insider Buying and Selling at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.30% of the company’s stock.

Hedge Funds Weigh In On DexCom

A number of hedge funds have recently added to or reduced their stakes in the stock. Versant Capital Management Inc purchased a new stake in shares of DexCom in the fourth quarter valued at approximately $25,000. Riverview Trust Co raised its position in DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 232 shares in the last quarter. RPg Family Wealth Advisory LLC bought a new stake in DexCom during the 3rd quarter valued at $57,000. Covestor Ltd lifted its holdings in shares of DexCom by 53.7% in the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after buying an additional 335 shares during the period. Finally, MassMutual Private Wealth & Trust FSB grew its position in shares of DexCom by 46.7% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after buying an additional 265 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

DexCom Trading Down 0.5 %

DXCM stock opened at $84.38 on Monday. DexCom has a 12 month low of $62.34 and a 12 month high of $142.00. The firm’s 50-day moving average is $78.17 and its 200 day moving average is $77.75. The company has a market capitalization of $32.96 billion, a PE ratio of 50.53, a P/E/G ratio of 2.00 and a beta of 1.12. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Canaccord Genuity Group upped their price target on shares of DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Royal Bank of Canada dropped their price objective on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Oppenheimer decreased their target price on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Finally, JPMorgan Chase & Co. increased their price target on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Five equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and a consensus price target of $99.29.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.